News

Curetis CE-IVD Blood Culture Cartridge

Jun 16, 2016 | NEW YORK (GenomeWeb) – Curetis said today that it has received the CE-IVD mark for its Unyvero BCU Blood Culture Application Cartridge and has launched the test in Europe, the Middle East, and Asia. The company said the launch was supported by interim data from an external, prospective, multicenter evaluation comparing…

Read More

Curetis Update

Curetis Publishes First Quarter 2016 Business and Financial Update – Worldwide commercial expansion and US FDA trial on track – Installed base of Unyvero Analyzers increased to 107 devices Amsterdam, the Netherlands and Holzgerlingen, Germany, May 20, 2016 — Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic…

Read More

Epigenomics Receives FDA Approval for Epi proColon

-First and only blood-based colorectal cancer screening test approved by the FDA -Innovative, convenient and effective screening option for millions of eligible Americans -Commercialization initiated with partner Polymedco Berlin (Germany) and Germantown, MD (U.S.A.), April 13, 2016 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that the…

Read More

GBC is Awarded NCI CPTAC Contract

Seattle-based Clinical Research Organization is Awarded a National Cancer Institute (NCI) Contract for Oncology Biospecimen Collection SEATTLE, March 30, 2016  Global BioClinical (GBC), http://www.globalbioclinical.com, is pleased to announce that it has been awarded a contract from the National Institutes of Health (NIH) / National Cancer Institute (NCI) to support the Clinical Proteomics Tumor Analysis Consortium (CPTAC)…

Read More

Curetis to Launch CE-IVD Unyvero Blood Culture Application Cartridge at ECCMID 2016

Curetis to Launch CE-IVD Unyvero Blood Culture Application Cartridge at ECCMID 2016 – Successful completion of CE Performance Evaluation Study – Covers 103 diagnostic targets with 87 pathogens and 16 resistance markers Amsterdam, the Netherlands and Holzgerlingen, Germany, March 23, 2016 — Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of…

Read More

Curetis Blood Culture CE-IVD

Curetis Validating Blood Culture Cartridge for CE-IVD Launch in Q2 Mar 03, 2016 NEW YORK (GenomeWeb) – In preparation for a CE-IVD launch in the second quarter, Curetis has initiated the final performance evaluation of its BCU Blood Culture Application cartridge to diagnose bloodstream infections. The Holzgerlingen, Germany-based company is also gathering momentum from its…

Read More

Curetis Validation of Blood Culture Cartridge

Curetis Starts Final Validation Study for New Unyvero Blood Culture Application Cartridge – Data and CE-IVD launch expected in Q2, 2016 – Company also prepares launch of 2nd generation ITI Application Cartridge and novel product for intra-abdominal infections Amsterdam, the Netherlands and Holzgerlingen, Germany, February 23, 2016 — Curetis N.V. (the “Company” and, together with…

Read More

Curetis Expands Commercial Team

Curetis Expands Commercial Team – Company hires Willem Haagmans as Head of Sales EMEA – Amsterdam, the Netherlands and Holzgerlingen, Germany, February 3, 2016 — Curetis N.V. (the “Company” and, together with Curetis AG, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced the expansion of its commercial and general administrative team. As of…

Read More

Curetis Medical Advisory Board

Curetis Establishes Medical Advisory Board with Internationally Renowned Experts Curetis AG, 11 Jan 16,  Amsterdam, The Netherlands, and Holzgerlingen, Germany, January 11, 2016 – Curetis N.V., a developer of next-level molecular diagnostic solutions for syndromic infectious disease testing, today announced the establishment of its Medical Advisory Board (MAB). Initially, it will consist of four leading experts…

Read More

Epigenomics Receives Notice of FDA Pending Approval

Epigenomics Receives FDA Notification About Status of Pending Approval Decision for Epi proColon® Berlin, Germany, January 8, 2016 – Epigenomics AG, Berlin, Germany, (Frankfurt Prime Standard: ECX; ISIN: DE000A11QW50) the German-American cancer molecular diagnostics company, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that the already submitted and available…

Read More